Prosecution Insights
Last updated: May 29, 2026

Mannkind Corporation

12 pending office actions • 8 art units • 9 examiners • 0 of 12 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days

Portfolio Summary

12
Total Pending OAs
8
Non-Final OAs
3
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
2
Due this month
5
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (2)Due ≤ 60 days (5)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
5
Medium (42%)
0
Easy (0%)
7
Unknown (58%)

Rejection Statute Mix

BucketCases
§103 only3 (25%)
Double-patenting + other2 (17%)
No statute on record7 (58%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
17% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HAGHIGHATIAN, MINA 4 45.8% +40.0%
VAJDA, KRISTIN ANN 1 84.1% +10.6%
WEBB, WALTER E 1 46.4% +18.6%
PIHONAK, SARAH 1 60.9% +43.4%
KRISHNAN, GANAPATHY 1 52.2% +0.0%
TIEN, LUCY MINYU 1 61.3% +35.6%
HOWELL, GWYNNETH LINNEA 1 42.4% +80.2%
MCDOWELL, BRIAN E 1 74.3% +30.6%
PHILIPS, BRADLEY H 1 67.1% +30.6%

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18524116 Diketopiperazine Salts for Drug Delivery and Related Methods HAGHIGHATIAN, MINA 131d overdue
17309624 Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them TIEN, LUCY MINYU 9d overdue
17983915 DRY POWDER INHALER HAGHIGHATIAN, MINA 1d overdue
17016158 METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS MCDOWELL, BRIAN E 9d
16932520 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY PHILIPS, BRADLEY H 33d
18367118 METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT WEBB, WALTER E 34d
17077712 APPARATUS, SYSTEM AND METHOD FOR DETECTING AND MONITORING INHALATIONS HOWELL, GWYNNETH LINNEA 34d
18744031 FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE VAJDA, KRISTIN ANN 48d

Top Art Units

Art UnitApps
1616 4
1612 2
1622 1
1627 1
1693 1
3785 1
1624 1
3799 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18744031 FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE VAJDA, KRISTIN ANN 1622 Other Final Rejection 48d Pending Jun 14, 2024
18524116 Diketopiperazine Salts for Drug Delivery and Related Methods HAGHIGHATIAN, MINA 1616 Other Non-Final OA 131d overdue Pending Nov 30, 2023
18367118 METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT WEBB, WALTER E 1612 Other Non-Final OA 34d Pending Sep 12, 2023
18265660 Method and Composition for Treating Pulmonary Fibrosis PIHONAK, SARAH 1627 DPOther Non-Final OA 61d Pending Jun 06, 2023
17983915 DRY POWDER INHALER HAGHIGHATIAN, MINA 1616 Other Non-Final OA 1d overdue Pending Nov 09, 2022
17864828 Delivery of Active Agents KRISHNAN, GANAPATHY 1693 Other Non-Final OA 22d Pending Jul 14, 2022
17309624 Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them TIEN, LUCY MINYU 1612 §103 Non-Final OA 9d overdue Pending Jun 10, 2021
17244730 DRY POWDER DRUG DELIVERY SYSTEM HAGHIGHATIAN, MINA 1616 Other Final Rejection 48d Pending Apr 29, 2021
17158997 DRY POWDER INHALER HAGHIGHATIAN, MINA 1616 DPOther Non-Final OA Pending Jan 26, 2021
17077712 APPARATUS, SYSTEM AND METHOD FOR DETECTING AND MONITORING INHALATIONS HOWELL, GWYNNETH LINNEA 3785 §103 Final Rejection 34d Pending Oct 22, 2020
17016158 METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS MCDOWELL, BRIAN E 1624 §103 Non-Final OA 9d Pending Sep 09, 2020
16932520 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY PHILIPS, BRADLEY H 3799 Other Non-Final OA 33d Pending Jul 17, 2020

Managing Mannkind Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month